Cardiac Electronic Implantable Devices in the Treatment of Heart Failure

Heart Lung and Circulation

Volumn 21, Issue 6-7, 2012, Pages 338-351

  Tan, Timothy C ^a,b   Sindone, Andrew P ^c   Denniss, A Robert ^a,d  

^a WESTMEAD HOSPITAL   (Australia)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Department of Geriatric Medicine   (Australia)

^d BLACKTOWN HOSPITAL   (Australia)

Author keywords

Cardiac resynchronisation therapy; CRT; Device therapy; Heart failure; ICD; Implantable cardiac defibrillators

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DIGOXIN; METOPROLOL; PLACEBO;

ACUTE HEART INFARCTION; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DEFIBRILLATOR; DEVICE THERAPY; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FUNCTION; HEART VENTRICLE PERFORMANCE; HEART VENTRICLE TACHYCARDIA; HUMAN; INTERMETHOD COMPARISON; LEFT VENTRICULAR ASSIST DEVICE; MORBIDITY; MORTALITY; PATIENT SELECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; QRS COMPLEX; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SUDDEN DEATH; SYMPTOM; SYNCOPE; SYSTOLIC DYSFUNCTION; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

AUSTRALIA; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; PREVALENCE; SURVIVAL RATE;

EID: 84862156821     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2012.03.124     Document Type: Article

References (122)

1. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993, 22(4 Suppl. A):6A-13A.
2. Krum H., Jelinek M.V., Stewart S., Sindone A., Atherton J.J., Hawkes A.L. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust 2006, 185(10):549-557.
3. Garg R., Packer M., Pitt B., Yusuf S. Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993, 22(4 Suppl. A):3A-5A.
4. McMurray J.J., Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000, 83(5):596-602.
5. Department of Health WA Heart failure model of care 2008, Health Networks Branch, Department of Health, Western Australia, Perth.
6. Boehmer J.P. Device therapy for heart failure. Am J Cardiol 2003, 91(6A):53D-59D.
7. Johnson R.A., Palacios I. Dilated cardiomyopathies of the adult (second of two parts). N Engl J Med 1982, 307(18):1119-1126.
8. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347(18):1397-1402.
9. Stewart S., Jenkins A., Buchan S., McGuire A., Capewell S., McMurray J.J. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002, 4(3):361-371.
10. O'Connell J.B. The economic burden of heart failure. Clin Cardiol 2000, 23(3 Suppl.):III6-III10.
11. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353(9169):2001-2007.
12. Katz A.M. Proliferative signaling and disease progression in heart failure. Circ J 2002, 66(3):225-231.
13. Turer A.T., Rao S.V. Device therapy in the management of congestive heart failure. Cardiol Rev 2005, 13(3):130-138.
14. Rose E.A., Gelijns A.C., Moskowitz A.J., Heitjan D.F., Stevenson L.W., Dembitsky W., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345(20):1435-1443.
15. Aaronson K.D., Schwartz J.S., Chen T.M., Wong K.L., Goin J.E., Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95(12):2660-2667.
16. Shamim W., Francis D.P., Yousufuddin M., Varney S., Pieopli M.F., Anker S.D., et al. Intraventricular conduction delay: a prognostic marker in chronic heart failure. Int J Cardiol 1999, 70(2):171-178.
17. Jong P., Vowinckel E., Liu P.P., Gong Y., Tu J.V. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002, 162(15):1689-1694.
18. Poole-Wilson P.A., Uretsky B.F., Thygesen K., Cleland J.G., Massie B.M., Ryden L. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003, 89(1):42-48.
19. Cannom D.S., Prystowsky E.N. Evolution of the implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2004, 15(3):375-385.
20. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997, 337(22):1576-1583.
21. Goldman S., Johnson G., Cohn J.N., Cintron G., Smith R., Francis G. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87(6 Suppl.):VI24-VI31.
22. Josephson M., Wellens H.J. Implantable defibrillators and sudden cardiac death. Circulation 2004, 109(22):2685-2691.
23. Saxon LA, De Marco T. Resynchronization therapy for heart failure. Educational content from the Heart Rhythm Society website; 2003.
24. Denniss A.R., Richards D.A., Waywood J.A., Yung T., Kam C.A., Ross D.L., et al. Electrophysiological and anatomic differences between canine hearts with inducible ventricular tachycardia and fibrillation associated with chronic myocardial infarction. Circ Res 1989, 64(1):155-166.
25. Jackson G., Gibbs C.R., Davies M.K., Lip G.Y. ABC of heart failure. Pathophysiology. BMJ 2000, 320(7228):167-170.
26. Garguichevich J.J., Ramos J.L., Gambarte A., Gentile A., Hauad S., Scapin O., et al. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J 1995, 130(3 Pt 1):494-500.
27. Massie B.M., Fisher S.G., Radford M., Deedwania P.C., Singh B.N., Fletcher R.D., et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 1996, 93(12):2128-2134.
28. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352(3):225-237.
29. Piccini J.P., Berger J.S., O'Connor C.M. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009, 30(10):1245-1253.
30. Kuck K.H., Cappato R., Siebels J., Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000, 102(7):748-754.
31. Connolly S.J., Hallstrom A.P., Cappato R., Schron E.B., Kuck K.H., Zipes D.P., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000, 21(24):2071-2078.
32. Bokhari F., Newman D., Greene M., Korley V., Mangat I., Dorian P. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004, 110(2):112-116.
33. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346(12):877-883.
34. Pires L.A., Hull M.L., Nino C.L., May L.M., Ganji J.R. Sudden death in recipients of transvenous implantable cardioverter defibrillator systems: terminal events, predictors, and potential mechanisms. J Cardiovasc Electrophysiol 1999, 10(8):1049-1056.
35. Pires L.A., Lehmann M.H., Steinman R.T., Baga J.J., Schuger C.D. Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses. J Am Coll Cardiol 1999, 33(1):24-32.
36. Myerburg R.J., Kessler K.M., Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 1992, 85(1 Suppl.):I2-I10.
37. Pires L.A. Implantable devices for management of chronic heart failure: defibrillators and biventricular pacing therapy. Curr Opin Anaesthesiol 2006, 19(1):69-74.
38. Gregoratos G., Abrams J., Epstein A.E., Freedman R.A., Hayes D.L., Hlatky M.A., et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol 2002, 13(11):1183-1199.
39. Moss A.J., Hall W.J., Cannom D.S., Daubert J.P., Higgins S.L., Klein H., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996, 335(26):1933-1940.
40. Bigger J.T. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997, 337(22):1569-1575.
41. Denniss A.R., Ross D.L., Richards D.A., Holley L.K., Cooper M.J., Johnson D.C., et al. Differences between patients with ventricular tachycardia and ventricular fibrillation as assessed by signal-averaged electrocardiogram, radionuclide ventriculography and cardiac mapping. J Am Coll Cardiol 1988, 11(2):276-283.
42. Strickberger S.A., Hummel J.D., Bartlett T.G., Frumin H.I., Schuger C.D., Beau S.L., et al. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003, 41(10):1707-1712.
43. Kadish A., Dyer A., Daubert J.P., Quigg R., Estes N.A., Anderson K.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350(21):2151-2158.
44. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999, 341(25):1882-1890.
45. Wilber D.J., Zareba W., Hall W.J., Brown M.W., Lin A.C., Andrews M.L., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004, 109(9):1082-1084.
46. Teerlink J.R., Jalaluddin M., Anderson S., Kukin M.L., Eichhorn E.J., Francis G., et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 2000, 101(1):40-46.
47. Hohnloser S.H., Dorian P., Straub M., Beckmann K., Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol 2004, 44(1):99-104.
48. Halkin A., Singh M., Nikolsky E., Grines C.L., Tcheng J.E., Garcia E., et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005, 45(9):1397-1405.
49. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352(11):1071-1080.
50. Zaman S., Sivagangabalan G., Narayan A., Thiagalingam A., Ross D.L., Kovoor P. Outcomes of early risk stratification and targeted implantable cardioverter-defibrillator implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Circulation 2009, 120(3):194-200.
51. Estes N.A. The challenge of predicting and preventing sudden cardiac death immediately after myocardial infarction. Circulation 2009, 120(3):185-187.
52. Tung R., Zimetbaum P., Josephson M.E. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008, 52(14):1111-1121.
53. Epstein A.E., DiMarco J.P., Ellenbogen K.A., Estes N.A., Freedman R.A., Gettes L.S., et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 51(21):e1-e62.
54. Zhou Q., Henein M., Coats A., Gibson D. Different effects of abnormal activation and myocardial disease on left ventricular ejection and filling times. Heart 2000, 84(3):272-276.
55. Kass D.A., Chen C.H., Curry C., Talbot M., Berger R., Fetics B., et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999, 99(12):1567-1573.
56. Xiao H.B., Roy C., Fujimoto S., Gibson D.G. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol 1996, 53(2):163-170.
57. Littmann L., Symanski J.D. Hemodynamic implications of left bundle branch block. J Electrocardiol 2000, 33(Suppl.):115-121.
58. Denniss A.R., Richards D.A., Cody D.V., Russell P.A., Young A.A., Cooper M.J., et al. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 1986, 74(4):731-745.
59. Baldasseroni S., Opasich C., Gorini M., Lucci D., Marchionni N., Marini M., et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002, 143(3):398-405.
60. Cazeau S., Ritter P., Bakdach S., Lazarus A., Limousin M., Henao L., et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol 1994, 17(11 Pt 2):1974-1979.
61. Nelson G.S., Berger R.D., Fetics B.J., Talbot M., Spinelli J.C., Hare J.M., et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 2000, 102(25):3053-3059.
62. Eichhorn E.J., Heesch C.M., Barnett J.H., Alvarez L.G., Fass S.M., Grayburn P.A., et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994, 24(5):1310-1320.
63. Pachon J.C., Pachon E.I., Albornoz R.N., Kormann D.S., Gimenes V.M., Medeiros P.T., et al. Ventricular endocardial right bifocal stimulation in the treatment of severe dilated cardiomyopathy heart failure with wide QRS. Pacing Clin Electrophysiol 2001, 24(9 Pt 1):1369-1376.
64. Auricchio A., Stellbrink C., Block M., Sack S., Vogt J., Bakker P., et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation 1999, 99(23):2993-3001.
65. Van Bommel R.J., Delgado V., Schalij M.J., Bax J.J. Critical appraisal of the use of cardiac resynchronization therapy beyond current guidelines. J Am Coll Cardiol 2010, 56(10):754-762.
66. Cazeau S., Leclercq C., Lavergne T., Walker S., Varma C., Linde C., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344(12):873-880.
67. Abraham W.T., Fisher W.G., Smith A.L., Delurgio D.B., Leon A.R., Loh E., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346(24):1845-1853.
68. Saxon L.A., De Marco T. Cardiac resynchronization: a cornerstone in the foundation of device therapy for heart failure. J Am Coll Cardiol 2001, 38(7):1971-1973.
69. Saxon L.A., Boehmer J.P., Hummel J., Kacet S., De Marco T., Naccarelli G., et al. Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. The VIGOR CHF and VENTAK CHF Investigators. Am J Cardiol 1999, 83(5B):120D-123D.
70. Bradley D.J., Bradley E.A., Baughman K.L., Berger R.D., Calkins H., Goodman S.N., et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003, 289(6):730-740.
71. Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De Marco T., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350(21):2140-2150.
72. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352(15):1539-1549.
73. Young J.B., Abraham W.T., Smith A.L., Leon A.R., Lieberman R., Wilkoff B., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003, 289(20):2685-2694.
74. Higgins S.L., Hummel J.D., Niazi I.K., Giudici M.C., Worley S.J., Saxon L.A., et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003, 42(8):1454-1459.
75. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26(11):1115-1140.
76. Konstantino Y., Iakobishvili Z., Arad O., Ben-Gal T., Kusniec J., Mazur A., et al. Urgent cardiac resynchronization therapy in patients with decompensated chronic heart failure receiving inotropic therapy. A case series. Cardiology 2006, 106(1):59-62.
77. Krum H., Jelinek M.V., Stewart S., Sindone A., Atherton J.J. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust 2011, 194(8):405-409.
78. Herweg B., Ilercil A., Cutro R., Dewhurst R., Krishnan S., Weston M., et al. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure. Am J Cardiol 2007, 100(1):90-93.
79. Cowburn P.J., Patel H., Jolliffe R.E., Wald R.W., Parker J.D. Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure?. Eur J Heart Fail 2005, 7(2):215-217.
80. James K.B., Militello M., Barbara G., Wilkoff B.L. Biventricular pacing for heart failure patients on inotropic support: a review of 38 consecutive cases. Tex Heart Inst J 2006, 33(1):19-22.
81. Chung E.S., Leon A.R., Tavazzi L., Sun J.P., Nihoyannopoulos P., Merlino J., et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008, 117(20):2608-2616.
82. Goldenberg I., Moss A.J., Hall W.J., Foster E., Goldberger J.J., Santucci P., et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011, 124(14):1527-1536.
83. Shenkman H.J., Pampati V., Khandelwal A.K., McKinnon J., Nori D., Kaatz S., et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest 2002, 122(2):528-534.
84. Beshai J.F., Grimm R.A., Nagueh S.F., Baker J.H., Beau S.L., Greenberg S.M., et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007, 357(24):2461-2471.
85. Linde C., Abraham W.T., Gold M.R., St John Sutton M., Ghio S., Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008, 52(23):1834-1843.
86. Cazeau S.J., Daubert J.C., Tavazzi L., Frohlig G., Paul V. Responders to cardiac resynchronization therapy with narrow or intermediate QRS complexes identified by simple echocardiographic indices of dyssynchrony: the DESIRE study. Eur J Heart Fail 2008, 10(3):273-280.
87. Marwick T.H., Grimm R.A. Extending the use of cardiac resynchronization therapy: do we need a new algorithm?. J Am Coll Cardiol 2010, 56(10):763-765.
88. Ellenbogen K.A., Gold M.R., Meyer T.E., Fernndez Lozano I., Mittal S., Waggoner A.D., et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010, 122(25):2660-2668.
89. Zareba W., Klein H., Cygankiewicz I., Hall W.J., McNitt S., Brown M., et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011, 123(10):1061-1072.
90. Byrne M.J., Helm R.H., Daya S., Osman N.F., Halperin H.R., Berger R.D., et al. Diminished left ventricular dyssynchrony and impact of resynchronization in failing hearts with right versus left bundle branch block. J Am Coll Cardiol 2007, 50(15):1484-1490.
91. Auricchio A., Fantoni C., Regoli F., Carbucicchio C., Goette A., Geller C., et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004, 109(9):1133-1139.
92. Fantoni C., Kawabata M., Massaro R., Regoli F., Raffa S., Arora V., et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol 2005, 16(2):112-119. discussion 20-1.
93. Vassallo J.A., Cassidy D.M., Marchlinski F.E., Buxton A.E., Waxman H.L., Doherty J.U., et al. Endocardial activation of left bundle branch block. Circulation 1984, 69(5):914-923.
94. Bax J.J., Ansalone G., Breithardt O.A., Derumeaux G., Leclercq C., Schalij M.J., et al. Echocardiographic evaluation of cardiac resynchronization therapy: ready for routine clinical use? A critical appraisal. J Am Coll Cardiol 2004, 44(1):1-9.
95. Leon A.R., Abraham W.T., Brozena S., Daubert J.P., Fisher W.G., Gurley J.C., et al. Cardiac resynchronization with sequential biventricular pacing for the treatment of moderate-to-severe heart failure. J Am Coll Cardiol 2005, 46(12):2298-2304.
96. Lim S.H., Lip G.Y., Sanderson J.E. Ventricular optimization of biventricular pacing: a systematic review. Europace 2008, 10(8):901-906.
97. Sutherland G.R., Kukulski T., Kvitting J.E., D'Hooge J., Arnold M., Brandt E., et al. Quantitation of left-ventricular asynergy by cardiac ultrasound. Am J Cardiol 2000, 86(4A):4G-9G.
98. Bax J.J., Abraham T., Barold S.S., Breithardt O.A., Fung J.W., Garrigue S., et al. Cardiac resynchronization therapy: Part 2-issues during and after device implantation and unresolved questions. J Am Coll Cardiol 2005, 46(12):2168-2182.
99. Baker J.H., McKenzie J., Beau S., Greer G.S., Porterfield J., Fedor M., et al. Acute evaluation of programmer-guided AV/PV and VV delay optimization comparing an IEGM method and echocardiogram for cardiac resynchronization therapy in heart failure patients and dual-chamber ICD implants. J Cardiovasc Electrophysiol 2007, 18(2):185-191.
100. Ritter P, Delnoy PP, Padeletti L, Lunati M, Naegele H, Borri-Brunetto A, Silvestre J., A randomized pilot study of optimization of cardiac resynchronization therapy in sinus rhythm patients using a peak endocardial acceleration sensor vs. Standard methods. Europace. 2012.
101. Carson P.E., Johnson G.R., Dunkman W.B., Fletcher R.D., Farrell L., Cohn J.N. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87(6 Suppl.):VI102-VI110.
102. Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91(6A):2D-8D.
103. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98(10):946-952.
104. Gasparini M., Regoli F., Galimberti P., Ceriotti C., Cappelleri A. Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace 2009, 11(Suppl. 5):v82-v86.
105. Lau C.P., Jiang Z.Y., Tang M.O. Efficacy of ventricular rate stabilization by right ventricular pacing during atrial fibrillation. Pacing Clin Electrophysiol 1998, 21(3):542-548.
106. Simpson C.S., Yee R., Lee J.K., Braney M., Klein G.J., Krahn A.D., et al. Safety and feasibility of a novel rate-smoothed ventricular pacing algorithm for atrial fibrillation. Am Heart J 2001, 142(2):294-300.
107. Kerr A.J., Williams M.J., Stewart R.A. Ventricular rate and beat-to-beat variation of stroke volume in atrial fibrillation. Am J Cardiol 2001, 87(9):1116-1119. A9.
108. Brignole M., Gammage M., Puggioni E., Alboni P., Raviele A., Sutton R., et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J 2005, 26(7):712-722.
109. Doshi R.N., Daoud E.G., Fellows C., Turk K., Duran A., Hamdan M.H., et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005, 16(11):1160-1165.
110. Dickstein K., Vardas P.E., Auricchio A., Daubert J.C., Linde C., McMurray J., et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010, 31(21):2677-2687.
111. Jaski B.E., Kim J., Maly R.S., Branch K.R., Adamson R., Favrot L.K., et al. Effects of exercise during long-term support with a left ventricular assist device. Results of the experience with left ventricular assist device with exercise (EVADE) pilot trial. Circulation 1997, 95(10):2401-2406.
112. Mancini D., Goldsmith R., Levin H., Beniaminovitz A., Rose E., Catanese K., et al. Comparison of exercise performance in patients with chronic severe heart failure versus left ventricular assist devices. Circulation 1998, 98(12):1178-1183.
113. Jaski B.E., Lingle R.J., Kim J., Branch K.R., Goldsmith R., Johnson M.R., et al. Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial. J Heart Lung Transplant 1999, 18(11):1031-1040.
114. Grady K.L., Meyer P., Mattea A., White-Williams C., Ormaza S., Kaan A., et al. Improvement in quality of life outcomes 2 weeks after left ventricular assist device implantation. J Heart Lung Transplant 2001, 20(6):657-669.
115. Noon G.P., Morley D.L., Irwin S., Abdelsayed S.V., Benkowski R.J., Lynch B.E. Clinical experience with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg 2001, 71(3 Suppl.):S133-S138. discussion S44-6.
116. Wieselthaler G.M., Schima H., Lassnigg A.M., Dworschak M., Pacher R., Grimm M., et al. Lessons learned from the first clinical implants of the DeBakey ventricular assist device axial pump: a single center report. Ann Thorac Surg 2001, 71(3 Suppl.):S139-S143. discussion S44-6.
117. Salzberg S., Lachat M., Zund G., Oechslin E., Schmid E.R., DeBakey M., et al. Left ventricular assist device as bridge to heart transplantation-lessons learned with the MicroMed DeBakey axial blood flow pump. Eur J Cardiothorac Surg 2003, 24(1):113-118.
118. Mudawi T.O., Kaye G.C. Implantable cardiac devices - past, present and future. British Journal of Cardiology 2008, 15(1):23-28.
119. Varma N., Epstein A.E., Irimpen A., Schweikert R., Love C. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation 2010, 122(4):325-332.
120. Crossley G.H., Boyle A., Vitense H., Chang Y., Mead R.H. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol 2011, 57(10):1181-1189.
121. Bardy G.H., Smith W.M., Hood M.A., Crozier I.G., Melton I.C., Jordaens L., et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010, 363(1):36-44.
122. Groeneveld P.W., Suh J.J., Matta M.A. The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review. J Interv Cardiol 2007, 20(1):1-9.